Search clinical trials for: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

Total 210 results

GlaxoSmithKline
Parexel

Completed

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI)

Asthma

United States, Australia, Poland, Russian Federation, Spain, Ukraine, Germany, Bulgaria, Argentina, Peru, South Africa, Taiwan, Belgium, Italy, Hungary, Korea, Republic of, Austria, Romania, Colombia, Slovakia, United Kingdom, Mexico and more
Professor Warren Lenney

Completed

Management of Asthma in School-age Children on Therapy (MASCOT)

Asthma
St. Joseph's Healthcare Hamilton
GlaxoSmithKline

Completed

Relative Potency of Inhaled Corticosteroids

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Canada
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Asthma

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, Spain, Netherlands, Hungary, Denmark, Poland, Czechia
University of Wisconsin, Madison
University of California, San Diego; National Heart, Lung, and Blood Institute... and other collaborators

Completed

DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations? (DREAM)

Lung Disease

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Asthma

United States, Canada, Czechia, Hungary, Poland, Russian Federation, South Africa, Ukraine
Research in Real-Life Ltd
Mundipharma Research Limited

Completed

Real-world Effectiveness of Combination Therapy in Asthma

Asthma

United Kingdom
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
GlaxoSmithKline

Completed

Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients

Asthma
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment

Pulmonary Disease, Chronic Obstructive
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Asthma | Bioequivalence

Greece
GlaxoSmithKline

Completed

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Ukraine, Spain, South Africa, Italy
Novartis
Merck Sharp & Dohme LLC

Completed

Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma

Asthma

France, Germany
NYU Langone Health
National Institute for Occupational Safety and Health (NIOSH/CDC)

Completed

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

Lung Diseases | Medication Compliance

United States
GlaxoSmithKline

Completed

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). (ADC111114)

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
Boehringer Ingelheim

Completed

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Cardiovascular Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Czech Republic, Denmark, Germany, Hungary, Netherlands, Spain, Sweden
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Asthma, Allergic

China
GlaxoSmithKline

Completed

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Asthma

Canada, Bulgaria, Estonia, Spain, Netherlands, Germany, Australia, Austria, Belgium, Finland, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, New Zealand, United Kingdom
Inje University

Completed

The Effects of Montelukast on Smokers With Asthma

Asthmatic Smokers | Non-asthmatic Smokers

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Romania, Russian Federation, United States, Ukraine
Organon and Co

Completed

Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)

Asthma
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Seoul National University Hospital

Completed

Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)

Pulmonary Disease, Chronic Obstructive

Korea, Republic of
Taipei Veterans General Hospital, Taiwan
GlaxoSmithKline

Unknown

Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA

COPD

Taiwan
Guangzhou Institute of Respiratory Disease

Completed

AMP-BPT and His-BPT for Assessment of Asthma (AMPHis)

Asthma
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
University of Florida
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose-Response of Salmeterol in Children

Asthma

United States
National Jewish Health

Completed

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Asthma

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
JHSPH Center for Clinical Trials
GlaxoSmithKline

Completed

The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma (CONNECT2)

Asthma

United States
Acer Therapeutics Inc.

Completed

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Post-menopausal Vasomotor Symptoms

United States
National Jewish Health
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

Obesity | Asthma

United States
Boehringer Ingelheim

Completed

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Denmark, France, South Africa, Austria, Belgium, Sweden
GlaxoSmithKline

Completed

Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season

Asthma | Rhinitis, Allergic, Seasonal

Germany
McGill University Health Centre/Research Institute...
GlaxoSmithKline

Completed

Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation

Chronic Obstructive Pulmonary Disease | COPD

Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (EXPEDITION)

Asthma

Denmark, United States, Canada, Germany, Sweden, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Asthma

United States, Brazil, China, Guatemala, India, Japan, Latvia, Mexico, Peru, Poland, Russian Federation
Brigham and Women's Hospital
Massachusetts General Hospital; Baim Institute for Clinical Research

Terminated

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations (GABLE)

Asthma

United States
GlaxoSmithKline

Completed

Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Asthma

United States, Brazil, China, Colombia, Germany, India, Japan, Mexico, Peru, Poland, Romania
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Research in Real-Life Ltd
Chiesi Farmaceutici S.p.A.

Completed

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management (Fos/Ser_switch)

Asthma

United Kingdom

3

Subscribe